The Use of Daratumumab in Relapsed Refractory Multiple Myeloma and Clinical Experience
Letter to the Editor
DOI:
https://doi.org/10.5281/zenodo.18663727Keywords:
Relapsed Refractory Multiple Myeloma, daratumumab, survivalAbstract
Dear Editor, we observed that daratumumab provided a survival advantage in the RRMM patient group with low survival rates. Its use in combination therapies with bortezomib from PIs and lenalidomide and pomalidomide from IMIDs has resulted in increased in both overall and progression-free survival. Although drug-related reactions were more common with the intravenous formulation, as shown in previous studies, we did not encounter them with the subcutaneous formulation. The subcutaneous formulation also facilitates ease of administration and patient compliance. Adverse events that developed with the use of the drug were managed according to standard care protocols. Our experience supports daratumumab as an effective and reliable treatment option based on real-world data.
References
1.Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., ... & Voorhees, P. M. (2016). Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. The Lancet, 387(10027), 1551-1560.
2.Sonneveld, P., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., ... & Spencer, A. (2023). Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial. Journal of Clinical Oncology, 41(8), 1600-1609.
3.Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., ... & Moreau, P. (2023). Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial. Journal of Clinical Oncology, 41(8), 1590-1599.
4.Mateos, M. V., Nahi, H., Legiec, W., Grosicki, S., Vorobyev, V., Spicka, I., ... & Usmani, S. Z. (2020). Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. The lancet haematology, 7(5), e370-e380.
5.Dimopoulos, M. A., Terpos, E., Boccadoro, M., Delimpasi, S., Beksac, M., Katodritou, E., ... & Zweegman, S. (2021). Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. The Lancet Oncology, 22(6), 801-812.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 KÜBRA ORAL
This work is licensed under a Creative Commons Attribution 4.0 International License.
